HuSignature™
Stratify patients that may benefit from your therapy

Discover and validate genetic signatures of response leveraging the extensive HuPrime® patient-derived xenograft (PDX) model collection.

Use HuSignature to find models that match your genetic signatures of interest, or responder and non-responder populations. All from a richly diverse collection of human surrogate PDX models, available for immediate drug discovery efficacy studies.

- Determine or validate relevant gene signatures or pathways related to response.
- Perform “Phase II-like” mouse clinical trials (HuTrial™) to stratify patient responders and non-responders.
- Characterize potential biomarkers of response.
- Identify novel indications for existing drugs.
- Manage life cycle of existing treatments.
- Constantly growing diverse collection of PDX with patient-relevant mutations.

KRAS Mutation vs Activating Oncogenic Alleles for Cetuximab Sensitivity in CRC PDX Models.

Per KRAS codons 12/13 mutation rule: wild type vs mutations.

Per the set of oncogenic alleles rule: wild type/KRAS G13D vs at least one activating allele on KRAS G12C/D/V, -Q61X, -A146T, NRAS Q61X, AKT1 L52R, PIK3CA E545K/-Q546L and BRAF V600E.

Contact Sales
US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com

Schedule Scientific Consultation
Request a consultation to discuss your project.
consultation@crownbio.com

Explore Scientific Data
Log into HuBase to review PDX model data.
hubase.crownbio.com